RxDoctor Payments Data

Michael Yeates, DO

Family Medicine · Kaysville, UTNPI 1336394410

Payments from drug & device makers

$4,681in general payments, 2019–2025

Across 309 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$486
  • Abbott$302
  • Amarin Pharma, Inc.$259
  • Novo Nordisk$240
  • Pfizer$221
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,61699%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,681 in reported general payments places this provider in the 80th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$99,195
Medicare patients
161
Services billed
8,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide34$44,626
TrulicityDulaglutide17$42,300
EliquisApixaban34$32,934
MounjaroTirzepatide22$26,980
XareltoRivaroxaban23$23,333
ArexvyRsvpref3 Antigen/As01e/Pf71$21,469
JardianceEmpagliflozin17$20,264
MyrbetriqMirabegron36$16,536
FarxigaDapagliflozin Propanediol12$13,170
JanuviaSitagliptin Phosphate11$10,463
ShingrixVaricella-Zoster Ge/As01b/Pf48$10,392
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$8,260
Atorvastatin Calcium322$3,851
Omeprazole185$3,344
Levothyroxine Sodium246$2,976

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$212$69,28039 claims
Novo NordiskOzempic$240$44,62634 claims
PfizerEliquis$221$32,93434 claims
GSKArexvy, Shingrix$486$31,861119 claims
Johnson & JohnsonXarelto$159$23,33323 claims
Boehringer IngelheimJardiance$193$20,26417 claims
Astellas Pharma US IncMyrbetriq$206$16,53636 claims
AstraZenecaFarxiga$27$13,17012 claims
MerckJanuvia$109$10,46311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 928 family medicine providers in Utah.

Other family medicine in Kaysville

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →